-
1
-
-
79959713140
-
Fibroblast growth factors and their receptors in cancer
-
Wesche J, Haglund K, Haugsten EM. Fibroblast growth factors and their receptors in cancer. Biochem J 2011; 437: 199-213.
-
(2011)
Biochem J
, vol.437
, pp. 199-213
-
-
Wesche, J.1
Haglund, K.2
Haugsten, E.M.3
-
2
-
-
84876048479
-
Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives
-
Dieci MV, Arnedos M, Andre F, Soria JC. Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives. Cancer Discov 2013; 3: 264-279.
-
(2013)
Cancer Discov
, vol.3
, pp. 264-279
-
-
Dieci, M.V.1
Arnedos, M.2
Andre, F.3
Soria, J.C.4
-
3
-
-
80053493427
-
Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesis
-
Lieu C, Heymach J, Overman M et al. Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesis. Clin Cancer Res 2011; 17: 6130-6139.
-
(2011)
Clin Cancer Res
, vol.17
, pp. 6130-6139
-
-
Lieu, C.1
Heymach, J.2
Overman, M.3
-
4
-
-
70450175957
-
Targeting angiogenesis: progress with anti-VEGF treatment with large molecules
-
Grothey A, Galanis E. Targeting angiogenesis: progress with anti-VEGF treatment with large molecules. Nat Rev Clin Oncol 2009; 6: 507-518.
-
(2009)
Nat Rev Clin Oncol
, vol.6
, pp. 507-518
-
-
Grothey, A.1
Galanis, E.2
-
5
-
-
0036782278
-
VEGF and the quest for tumour angiogenesis factors
-
Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2002; 2: 795-803.
-
(2002)
Nat Rev Cancer
, vol.2
, pp. 795-803
-
-
Ferrara, N.1
-
6
-
-
84896691579
-
Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors
-
Dienstmann R, Rodon J, Prat A et al. Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors. Ann Oncol 2014; 25: 552-563.
-
(2014)
Ann Oncol
, vol.25
, pp. 552-563
-
-
Dienstmann, R.1
Rodon, J.2
Prat, A.3
-
7
-
-
79958112619
-
Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer
-
Dutt A, Ramos AH, Hammerman PS et al. Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. PLoS One 2011; 6: e20351.
-
(2011)
PLoS One
, vol.6
-
-
Dutt, A.1
Ramos, A.H.2
Hammerman, P.S.3
-
8
-
-
75149170979
-
Fibroblast growth factor signalling: from development to cancer
-
Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 2010; 10: 116-129.
-
(2010)
Nat Rev Cancer
, vol.10
, pp. 116-129
-
-
Turner, N.1
Grose, R.2
-
9
-
-
59449094654
-
Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array
-
Andre F, Job B, Dessen P et al. Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array. Clin Cancer Res 2009; 15: 441-451.
-
(2009)
Clin Cancer Res
, vol.15
, pp. 441-451
-
-
Andre, F.1
Job, B.2
Dessen, P.3
-
10
-
-
34447325266
-
FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis
-
Elbauomy ES, Green AR, Lambros MB et al. FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis. Breast Cancer Res 2007; 9: R23.
-
(2007)
Breast Cancer Res
, vol.9
-
-
Elbauomy, E.S.1
Green, A.R.2
Lambros, M.B.3
-
11
-
-
33845331706
-
FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas
-
Reis-Filho JS, Simpson PT, Turner NC et al. FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas. Clin Cancer Res 2006; 12: 6652-6662.
-
(2006)
Clin Cancer Res
, vol.12
, pp. 6652-6662
-
-
Reis-Filho, J.S.1
Simpson, P.T.2
Turner, N.C.3
-
12
-
-
77950866696
-
Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets
-
Turner N, Lambros MB, Horlings HM et al. Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. Oncogene 2010; 29: 2013-2023.
-
(2010)
Oncogene
, vol.29
, pp. 2013-2023
-
-
Turner, N.1
Lambros, M.B.2
Horlings, H.M.3
-
13
-
-
84879868244
-
FGFR1 and FGF coamplification in breast cancer
-
Albiges L, Albiges L, Quidville V et al. FGFR1 and FGF coamplification in breast cancer. Cancer Res 2009; 69(suppl 3): 4170.
-
(2009)
Cancer Res
, vol.69
, pp. 4170
-
-
Albiges, L.1
Albiges, L.2
Quidville, V.3
-
14
-
-
77950278598
-
FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer
-
Turner N, Pearson A, Sharpe R et al. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res 2010; 70: 2085-2094.
-
(2010)
Cancer Res
, vol.70
, pp. 2085-2094
-
-
Turner, N.1
Pearson, A.2
Sharpe, R.3
-
15
-
-
79951826312
-
E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models
-
Bello E, Colella G, Scarlato V et al. E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res 2011; 71: 1396-1405.
-
(2011)
Cancer Res
, vol.71
, pp. 1396-1405
-
-
Bello, E.1
Colella, G.2
Scarlato, V.3
-
17
-
-
0003563862
-
Study design principles for the clinical evaluation of new drugs as developed by the chemotherapy programme of the National Cancer Institute
-
Staquet MJ (ed). Brussels: Editions Scientifiques Europeenes
-
Carter SK. Study design principles for the clinical evaluation of new drugs as developed by the chemotherapy programme of the National Cancer Institute. In Staquet MJ (ed), The Design of Clinical Trials in Cancer Therapy. Brussels: Editions Scientifiques Europeenes 1973;242-289.
-
(1973)
The Design of Clinical Trials in Cancer Therapy
, pp. 242-289
-
-
Carter, S.K.1
-
19
-
-
57849117384
-
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
-
Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247.
-
(2009)
Eur J Cancer
, vol.45
, pp. 228-247
-
-
Eisenhauer, E.A.1
Therasse, P.2
Bogaerts, J.3
-
20
-
-
80054818768
-
Development and validation of a high-performance liquid chromatography-tandem mass spectrometry method for the determination of the novel inhibitor of angiogenesis E-3810 in human plasma and its application in a clinical pharmacokinetic study
-
Sala F, Bagnati R, Livi V et al. Development and validation of a high-performance liquid chromatography-tandem mass spectrometry method for the determination of the novel inhibitor of angiogenesis E-3810 in human plasma and its application in a clinical pharmacokinetic study. J Mass Spectrom 2011; 46: 1039-1045.
-
(2011)
J Mass Spectrom
, vol.46
, pp. 1039-1045
-
-
Sala, F.1
Bagnati, R.2
Livi, V.3
-
21
-
-
84904042903
-
Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents-Dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation for Research and Treatment of Cancer-led study
-
Postel-Vinay S, Collette L, Paoletti X et al. Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents-Dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation for Research and Treatment of Cancer-led study. Eur J Cancer 2014; 50: 2040-2049.
-
(2014)
Eur J Cancer
, vol.50
, pp. 2040-2049
-
-
Postel-Vinay, S.1
Collette, L.2
Paoletti, X.3
-
22
-
-
84893408764
-
Regulation of renal phosphate transport by FGF23 is mediated by FGFR1 and FGFR4
-
Gattineni J, Alphonse P, Zhang Q et al. Regulation of renal phosphate transport by FGF23 is mediated by FGFR1 and FGFR4. Am J Physiol Renal Physiol 2014; 306: F351-F358.
-
(2014)
Am J Physiol Renal Physiol
, vol.306
, pp. F351-F358
-
-
Gattineni, J.1
Alphonse, P.2
Zhang, Q.3
-
23
-
-
84859415553
-
Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer
-
Brooks AN, Kilgour E, Smith PD. Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer. Clin Cancer Res 2012; 18: 1855-1862.
-
(2012)
Clin Cancer Res
, vol.18
, pp. 1855-1862
-
-
Brooks, A.N.1
Kilgour, E.2
Smith, P.D.3
-
24
-
-
84910633715
-
A phase 3, multicenter, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid cancer (SELECT)
-
Schlumberger M, Tahara M, Wirth L et al. A phase 3, multicenter, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid cancer (SELECT). J Clin Oncol 2014; 32(suppl): LBA6008.
-
(2014)
J Clin Oncol
, vol.32
-
-
Schlumberger, M.1
Tahara, M.2
Wirth, L.3
-
25
-
-
77951296573
-
Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer
-
Barrios CH, Liu MC, Lee SC et al. Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. Breast Cancer Res Treat 2010; 121: 121-131.
-
(2010)
Breast Cancer Res Treat
, vol.121
, pp. 121-131
-
-
Barrios, C.H.1
Liu, M.C.2
Lee, S.C.3
-
26
-
-
84922981864
-
Results of a phase I study of AZD4547, an inhibitor of fibroblast growth factor receptor (FGFR) in patients with advanced solid tumors
-
Andre F, Ranson M, Dean E et al. Results of a phase I study of AZD4547, an inhibitor of fibroblast growth factor receptor (FGFR) in patients with advanced solid tumors. Cancer Res 2013; 73(suppl 1): LB-145.
-
(2013)
Cancer Res
, vol.73
-
-
Andre, F.1
Ranson, M.2
Dean, E.3
-
27
-
-
84871527692
-
A phase I dose escalation study of NVPBGJ398, a selective pan-FGRR inhibitor in genetically preselected advanced solid tumors
-
Wolf J, LoRusso PM, Camigde RD et al. A phase I dose escalation study of NVPBGJ398, a selective pan-FGRR inhibitor in genetically preselected advanced solid tumors. Cancer Res 2012; 72 (suppl 8): LC-122.
-
(2012)
Cancer Res
, vol.72
-
-
Wolf, J.1
LoRusso, P.M.2
Camigde, R.D.3
|